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Abstract: Despite numerous studies describing predominantly its demography and clinical 
course, many aspects of central serous chorioretinopathy (CSCR) remain unclear. Perhaps the 
major impediment to finding an effective therapy is the difficulty of performing studies with 
large enough cohorts, which has meant that clinicians have focused more on therapy than on 
a deeper understanding of the pathogenesis of the disease. Hypotheses on the pathogenesis of 
CSCR have ranged from a basic alteration in the choroid to an involvement of the retinal pigment 
epithelium (RPE). Starting from evidence that affected subjects often present a personality prone 
to stress with altered pituitary–hypothalamic axis response (HPA) and that they have higher 
levels of serum and urinary cortisol and catecholamines than healthy subjects, we hypothesize 
a cascade of events that may lead to CSCR through hypercoagulability and augmented platelet 
aggregation. In particular we investigated the role of tissue plasminogen activator, increasing 
plasminogen activator inhibitor 1 (PAI-1), and plasmin-α2- plasmin inhibitor complexes. 
We reviewed the different therapeutic approaches, including adrenergic antagonists, carbonic 
anhydrase inhibitors, mifepristone, ketoconazole, laser photocoagulation, intravitreal injection of 
bevacizumab, and photodynamic therapy with verteporfin (PDT) and our model of pathogenesis 
seems to be in agreement with the clinical effects obtained from these treatments. In accord 
with our thesis, we began to treat a group of patients affected by CSCR with low-dose aspirin 
(75–100 mg), because of its effectiveness in other vascular diseases and its low ocular and 
general toxicity with prolonged use. The formulation of a causative model of CSCR enables 
us to understand how the therapeutic approach cannot be based on a generalized therapy but 
should be individualized for each patient, and that sometimes a combined strategy of treatment 
is required. Moreover a complete knowledge of the disease will help to identify patients prone 
to the most persistent forms of CSCR, and thus help to find a treatment.
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Introduction
Central serous chorioretinopathy (CSCR) has been described by various names for 
nearly a century and a half.1–3 Despite numerous studies on this disease over the years, 
many aspects of CSCR remain unclear. Extensive literature describes predominantly 
its demography and the clinical course.4 The research has been limited by lack of 
homogeneity in the stage of CSCR in the cohort studies.
In general most authors have turned their attention to finding an effective strategy 
of treatment rather than trying to identify causes of, and contributing factors to, the 
occurrence of the CSCR.
Although CSCR has been described as a benign and self-limiting disease, it has a 
tendency to re-occur, with decreased visual function.5–7Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The need for early treatment emerges from   clinical 
evidence which stresses that if the resolution of the 
neuroepithelial detachment occurs within 4 months after onset 
of symptoms it is possible to reduce the incidence of retinal 
atrophy and the consequent decrease in visual acuity.8
Pathogenesis
Hypotheses on the pathogenesis of CSCR range from a basic 
alteration in the choroid to an involvement of the retinal pig-
ment epithelium (RPE).
As such, the treatment of CSCR has had either the RPE 
or choroid as the primary target, and sometimes effectiveness 
of therapy has been difficult to demonstrate. The advent of 
fluorescent angiography and indocyanine green angiography 
(ICGA) helped to improve understanding of the anatomical 
structure primarily involved in determining the development 
of the disease.9–13
A crucial breakthrough in understanding CSCR came 
from a report, that affected subjects often present a stressful 
personality with altered pituitary–hypothalamic axis (HPA) 
response.14
Furthermore, patients affected by CSCR often have higher 
levels of serum and urinary cortisol and catecholamines 
than healthy subjects.15–17 Subsequently it was reported 
that therapies with local or systemic steroids can cause the 
disease, and glucocorticoids were identified as the main risk 
factor for the onset of CSCR.18–20 Another consideration is 
that CSCR has also been described as a complication of 
diseases that have as their common denominator a condition 
of hypercoagulability and augmented platelet aggregation. 
These alterations can induce microthrombus formation and 
increase blood viscosity.21 It may be that these alterations are 
capable of affecting choroidal microcirculation.
Studies of eyes with CSCR using ICGA show abnormal 
choroidal perfusion and congestion of venous outflow.22,23
Circulatory disorders and areas of lobular hypoperfusion 
are frequently described in addition to an increased choroi-
dal permeability. These results, seemingly at odds, are the 
consequence of the same hemorheologic disorder underpin-
ning the onset of the CSCR. Effects of glucocorticoids on 
vascular reactivity24 have been described in patients affected 
by Cushing’s syndrome.
In this disease there is an augmented vascular response, 
due to the glucocorticoid excess, to noradrenaline and 
angiotensin II with consequent hypertensive response.25 
Administration of exogenous glucocorticoids in healthy 
volunteers was able to reproduce the same effect.26 
The application of glucocorticoids to conjunctiva or skin 
is able to determine a vasoconstrictive response27 that can 
be inhibited by the local or systemic administration of 
glucocorticoid antagonists.28
In addition, glucocorticoids increase platelet aggrega-
tion and, by causing a reduction in the tissue plasminogen 
activator and increasing plasminogen activator inhibitor 1 
(PAI-1) and the plasmin-α2- plasmin inhibitor complexes, 
create the condition for increased microthrombus formation 
and increased blood viscosity.29 Also patients with chronic 
psychological distress, with an increased reactivity of HPA, 
frequently show a condition of systemic hypertension induced 
by an increase in vascular resistance.30
Vascular bed reduction due to vasoconstriction and to 
capillary occlusion, combined with higher resistance and 
increased blood viscosity, determine a sectorial hypoperfu-
sion and an increase in the endoluminal pressure perfusion 
in the surrounding healthy vascular bed.
The increased endoluminal pressure determines the leak-
age of serum and small molecules in the stroma causing a 
further vascular tamponade. Since choroidal blood flow can 
be described by Hagen–Poiseuille’s law (∆P = 8 µLQ/πr4), 
it follows that small differences in total radius of vascular 
bed induce a high increase in endovascular pressure with 
fluid extravasation and, in the same direction, a variation in 
viscosity (µ) determines a modification of choriocapillaris 
hemodynamics.31–33
The affinity of the disease for the macular area is due 
to the particular organization of the choriocapillaris with a 
closer meshwork than the peripheral choroid.34
This cascade of events led by corticoids seems to be in 
agreement with documented observations of fluorescent 
angiography and ICGA obtained in CSCR patients.
Articles that highlight the occlusion or hypoperfusion 
of choricapillaris do not conflict with those that show an 
increase in capillary permeability but likely represent the 
same hemorheological alteration at different times. The 
anatomical impact of these hemoreologic variations com-
prises the decompensation and detachment of the RPE and 
the subsequent neuroepithelial detachment. At this stage the 
clinical appearance will be that of typical CSCR. This cascade 
of events is summarized in Figure 1.
Treatment
Evidence emerging from the studies of different therapeutic 
approaches seems to be in agreement with our proposed 
model of pathogenesis.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The use of adrenergic antagonists was one of the first 
attempts to treat CSCR. Adrenergic antagonists reduce the 
effect of vasoconstriction by blocking adrenergic receptor 
activation induced by glucorticoids.35 In order to reduce 
the adrenergic tone, thought to be behind the vasospastic 
  condition, even ablation of the stellate ganglion was used.36
Later treatment with α-adrenergic antagonists was tried,37 
then abandoned because of systemic side effects, and cur-
rently β-adrenergic antagonists are used because they have 
fewer side effects.38–41
Another attempt was made with the carbonic anhydrase 
inhibitors that act on RPE, contributing in part to the resorp-
tion of the subretinal fluid.42 Recent studies show that both 
systemic acetazolamide and dorzolamide for topical use 
can increase choroidal blood flow.43–45 In the specific case 
of CSCR, in which a deficiency of choroidal blood flow 
has been described, carbonic anhydrase inhibitors could 
be effective.
The difficulty in predicting which patients will face a 
chronic and relapsing disease, resulting in impaired visual 
function, has led to a search for drugs that can be effective in 
the treatment of CSCR by reducing the activity or the serum 
level of endogenous glucocorticoids. This pharmacological 
approach is interesting because it is directed against one of 
the better known factors in the genesis of the CSCR.
Mifepristone is an antagonist of glucocorticoids 
and   progesterone receptors with a weak antiandrogen 
action and has a good safety and tolerability profile. 
In   addition, mifepristone inhibits cortisol-induced   peripheral 
vasoconstriction. Ketoconazole exerts its effects by inhibit-
ing some steps in the steroid synthesis resulting in decreased 
  levels of cortisol, androgen, and aldosterone and in elevated 
progesterone. These effects seem to be present at the minimum 
dosage of 400 mg/day. An additional action of ketoconazole 
is the direct antiglucocorticoid effect as an antagonist at the 
receptor level. Current studies on these two medications are, 
however, limited by the short follow-up and the number of 
patients recruited.46–48 Moreover, use of both mifepristone and 
the ketaconazole may be limited by important side effects.
As noted previously, the advent of ICGA in the study of 
the characteristics of choroidal circulation in patients with 
CSCR, and the accumulation of clinical cases of CSCR 
linked to systemic diseases, suggested that a disorder of 
choroidal blood flow could be critical in the development 
of the disease.
The increase in procoagulant blood factors, in particular 
PAI-1, was found in patients with CSCR.21,49
Moreover an increase in platelet aggregation can be 
induced by glucocorticoids and these factors suggested to 
us that a treatment that improves choriocapillaris hemody-
namics and reduces PAI-1 could prevent the development 
of CSCR. We identified low-dose aspirin as a drug better 
suited for this purpose, because of its effectiveness in other 
vascular diseases and its low ocular and general toxicity 
with prolonged use.50,51 Besides its hemodynamic effects, 
aspirin reduces the stress response of the HPA axis, limiting 
the increase in serum cortisol and catecholamines.52,53 The 
putative mechanism of action of aspirin in the treatment of 
CSCR is therefore 2-fold: first, a purely hemoreologic action 
and, second, controlling the hyperfunction of the HPA axis. 
However aspirin, at greater doses, could have a paradoxical 
effect of vasoconstriction and predisposing to local and 
systemic hemorrhagic events. A dosage of 75 to 100 mg 
appears to be best, with a profile of effectiveness/side-effects 
as evidenced by extensive cardiologic trials.54,55
The pathogenetic model we have described appears to be 
in agreement with the effectiveness of laser photocoagula-
tion and photodynamic therapy with verteporfin in selected 
cases of CSCR.
Increased platelet aggregation
     PAI-1, tPA, 
plasmin-α2-plasmin inhibitor
(increased microthrombus
formation and increased
hematic viscosity)
Increased platelet aggregation
Relative endogenous hypercortisolism 
(or exogenous administration of corticoids)
        Lead to 
RPE DECOMPENSATION and DETACHMENT
 CENTRAL SEROUS CHORIORETINOPATHY
(In cases of prolonged course of disease or when risk factors persist, CSCR can become chronic or multifocal)
Reduced choroidal flow with impaired hemorheology
and increased probability of microthrombus formation.
Lobular choriocapillaris hypoperfusion
Increased intraluminal pressure in the surrounding
choriocapillaris (Hagen–Poiseuille’s Law) with extravasation of
serum and further tamponade of microvasculature
Direct steroids vasoconstriction
Indirect vasoconstriction
mediated by sensitization to
cathecolamines 
Suppression of local vasodilators
such
as prostacyclin and nitric oxide 
Figure 1 Central serous chorioretinopathy: a pathogenetic model.
Abbreviations: CSCr, central serous chorioretinopathy; PAi-1, plasminogen activator 
inhibitor 1; rPe, retinal pigment epithelium; tPA, tissue plasminogen activator.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The mechanism of action of laser photocoagulation in 
CSCR still seems unclear, given that a full-thickness pho-
tocoagulation is not needed to assess the effectiveness of 
treatment.
Recent theories speculate that the effectiveness of the 
treatment is due to activation of cytokines secreted from 
the RPE which reduces vascular permeability and rearranges 
the microvascular choroidal network.56
The effectiveness of verteporfin for CSCR, especially in 
chronic forms and with large areas of RPE decompensation, 
seems to be attributable to a reduction in the permeability of 
the hyperfluorescent areas seen by ICGA and to a subsequent 
remodeling of the vascular bed which could rebalance perfu-
sion pressure gradients previously altered.57
Intravitreal injection of bevacizumab is another recent 
approach to the treatment of CSCR.58 Growing   literature 
highlights how this type of treatment has a degree of 
effectiveness in reducing neuroepitelial detachment and 
choroidal hyperpermeability. The mechanism of action seems 
to be linked to a reduction in vascular permeability. However 
in CSCR an increase of vascular endothelial growth factor 
(VEGF) was not found in the aqueous humor.59 It is possible 
that bevacizumab acts on constitutional choroidal VEGF. The 
anti-VEGF treatment also increases occludin between RPE 
cells, increasing the external retinal barrier.60
Conclusion
The formulation of a causative model of CSCR allows us to 
understand how the therapeutic approach cannot be based on 
a generalized therapy but should be individualized for each 
patient, and that sometimes a combined strategy of treatment 
is required, which acts on the various steps that may deter-
mine the expression and maintenance of the disease.
To avoid the establishment of chronic disease, early 
intensive treatment is necessary to reduce the episodes of 
relapse.
In future a better discrimination of the precise molecular 
mechanisms involved in the susceptibility of individuals to 
glucocorticoids, and a more complete knowledge of the risk 
factors, could help to identify patients prone to the most 
persistent forms of CSCR.
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